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Neurotrophins play a crucial role in the differentiation, maintenance, and survival of various types of peripheral and central 
neurons. However, the therapeutic use of neurotrophins is limited by their inability to cross the blood-brain barrier and their 
instability in the bloodstream. One of the promising approaches to utilize neurotrophic actions of these molecules in the therapy of 
neurodegenerative diseases is the stimulation of neurotrophin synthesis. Here we review the effects of 4-methylcatechol, a 
nonadrenergic catechol compound, on the synthesis of the neurotrophins nerve growth factor and brain-derived neurotrophic 
factor in the peripheral and central nervous system. The neuroprotective potential of 4-methylcatechol in animal models of 




The nervous tissue appears to be able to compensate for some 
injuries by stimulating survival of neurons. However, it can not 
replace large populations of damaged neurons. This limitation 
was also proposed by Santiago Ramon y Cajal, who wrote ".. .in 
adult centers, the nerve paths are something fixed, ended, 
immutable. Every thing may die, nothing may be regenerated. It is 
for science of the future to change, if possible, this harsh 
decree." Although emerging evidence suggests in vivo 
neurogenesis in the adult brain (1), tremendous efforts of 
neuroscientists are continuing to be focused on the role played 
by neurotrophic factors in the pathobiology and therapy of both 
peripheral and central neurodegenerative diseases. 
The family of neurotrophins, including nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 
(NT)-3, NT-4/5, and NT-6, plays a crucial role in the differentiation, 
 
 
maintenance, and survival of distinct and overlapping neuronal 
populations within the central and peripheral nervous systems 
(CNS and PNS, respectively) (2-5). In addition, neurotrophins 
are related to neuronal plasticity (6,7). Neurotrophins are widely 
distributed in the CNS, and expressed at the highest level in the 
hippocampus and cerebral cortex (8-10). Expression of both 
mRNANGF and mRNABDNF is known to be regulated by glutamate or 
gamma-aminobutyric acid (GABA) neurotransmission (11-13). 
And evoked in association with various types of CNS and PNS 
injuries, such as sciatic nerve lesion (14,15), ischemic and 
traumatic injuries (11,16), and infusion of kainic acid (17) or 6-
hydroxydopamine (18,19) in the brain. These observations 
suggest an involvement of neurotrophins in the process of 
neuronal degeneration and regeneration. Indeed, intraventricular 
administration of BDNF prevents neuronal death of the nigral 
dopaminergic neurons induced by infusion of neurotoxins (20) 
or axotomy of nigrostriatal pathway (21,22). Likewise, 
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administration of NGF or BDNF suppresses neuronal death in 
the hippocampal pyramidal neurons following transient fore-
brain ischemia(23,24). Therefore, BDNF in particular, which has 
much wider action spectrum than NGF, is expected as a therapeutic 
agent for neurological disorders, such as Parkinson's disease, 
amyotrophic lateral screlosis, and Alzheimer' s disease. However, 
there are at least two obstacles against therapeutic application of 
neurotrophins to CNS diseases. First, neurotrophins are 
macromolecules that cannot pass through the blood-brain 
barrier (BBB), demonstrating a difficulty to deliver them from the 
periphery to the CNS. Second, neurotrophins may be rapidly 
incorporated into the liver due to their cationic charge (25), 
resulting in a short-term circulation in the bloodstream. Finally, 
an intraventricular infusion of neurotrophins as therapy involves 
serious technical and ethical problems. Further, transfection of 
BDNF gene with viral vectors, and transplantation of the cells 
engineered with BDNF gene may be promising approaches; a 
few reports demonstrate their effective protection against 
dopaminergic neurotoxins (26,27). However, the clinical security 
of these applications has not yet been fully established. A 
promising approach to utilize neurotrophic actions on the 
therapy is the stimulation of synthesis of neurotrophic factors. In 
this article, we review the effects of 4-methylcatechol (4MC) 
on the synthesis of NGF and BDNF in the PNS and CNS, and 
discuss its potential as a neuroprotective agent for degenerative 
neurological disorders. 
DISCOVERY OF CATECHOL COMPOUNDS THAT 
STIMULATE MGF SYNTHESIS IN VITRO 
In the PNS, NGF is synthesized predominantly in the target 
tissues of sympathetic neurons, taken up into the axons of these 
neurons and retrogradely transported into their cell bodies 
(28,29). NGFlevels and mRNA
NGF
 expression in the targettissue 
correlate with the density of sympathetic innervation (30). 
Moreover, nonneuronal cells, such as astrocytes, fibroblasts, 
and Schwann cells, are also responsible for NGF synthesis and 
release in target tissues. Accordingly, cell cultures are tested for 
NGF production, using a highly sensitive enzyme immunoas-
say for NGF (31) which enables to detect a small amount of NGF 
secreted into culture medium of primary fibroblasts (32) and a 
cell line of L-M fibroblasts (33). During investigation of regulatory 
mechanism(s) of NGF secretion in these cells, apotent stimulatory 
activity of a series of catechol compounds, including cate-
cholarnines, on NGF synthesis is found (33), Examination of the 
relationship between structure and activity clearly demonstrate 
that the stimulatory activity is based on the catechol ring and 
that the potency could be modulated by the side chain structure at 
the 4-position (34). A series of 4-alkylcatechols and their 
acetylated derivatives, which affect NGF synthesis without 
participation of adrenergic receptors, are documented to be 
potent stimulators of NGF production in vitro (35). In addition to 
fibroblasts, cultured astrocytes also produced NGF and their 
NGF production is markedly enhanced by catechol compounds 
(35,36). Additional active compounds such as propentofylline 
(37) and idebenone (38), which have chemical structures different 
fromcatechols, are found to exert the similar stimulatory activity in 
cultured astrocytes. The catechol compound 4MC has potent 
activity, and hence 4MC is used as a model compound that 
stimulates NGF synthesis. 
ENHANCEMENT OF NGF SYNTHESIS IN THE 
PERIPHERAL NERVOUS SYSTEM 
We assessed the action of 4MC on NGF production in rat 
tissues in vivo. After repeated injection of 4MC, the levels of 
NGF in heart and submaxillary glands is increased. The most 
effective dose (10 (ig/kg body weight) was much smaller than 
expected from the experiments in vitro. Single 4MC 
administration induces a transient increase in NGF and 
mRNA
NGF
 in the target organs. The increase in NGF level is also 
observed in the sciatic nerve. These results suggest retrograde 
axonal transport to the ganglia of the NGF induced in peripheral 
tissues in a manner similar to that occurs physiologically (39). 
Figure 1 illustrates 4MC-induced changes in NGF levels. 
Furthermore, chronic administration of 1,2-diacetoxy propyl 
benzene, an acetylated, stable form of 4MC analogue, caused 
significant elevations of substance P levels in dorsal root 
ganglia and tyrosine hydroxylase activity in superior cervical 
ganglia of infant rats. These observations suggest that these 
compounds could stimulate NGF synthesis in vivo, and that 
the induced NGF is physiologically active on peripheral 
neurons (39). 
STIMULATION OF PERIPHERAL NERVE REGENERATION 
Local administration of NGF at the injury site of the sciatic nerve 
has an influence on subsequent axonal regeneration (40), and 
NGF synthesis in nonneuronal cells is stimulated in response to 
sciatic nerve degeneration (41). These observations prompted us 
to test 4MC for peripheral nerve regeneration in a sciatic 
nerve-lesioned animal model. The sciatic nerve of adult male 
Wistar rats was transected and both of the cut ends were 
inserted into silicone tubes that were subsequently attached to 
an intervening silicone chamber. The rats were then injected 
intraperitoneally every day for 2 weeks with 10 J-tg/kg of 4MC. 
Two weeks after surgery, the density of nonmyelinated axons 
within the chamber was significantly increased in the 4MC-
treated group. Five weeks after surgery, both the number and 
the diameter of myelinated axons within the chamber of the 4MC-
treated group were significantly larger than those of the control 
group. When the chamber was filled with anti-NGF antibody 
solution, most of the 4MC effects were blocked. These 
observations suggest that 4MC stimulates de novo synthesis of 
NGF and/or NGF-related molecules such as BDNF, 
resulting in enhanced sprouting and maturation of proximal 
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Figure 1. Schematic representation of a time- or region-specific increase in NGF levels following a single intraperitoneal 
injection of4MC. In the heart and submaxillary gland, NGF content increased between 12 and 16 hr, and then decreased to the 
original level between 20 and 32 hr. The time-course of changes in NGF level in the sciatic nerve, which is one of the routes of NGF 
transport from the peripheral tissues to the ganglia, certifies axonal transport. Namely, the increase in NGF appears in the 
peripheral side at 20 hr, and it moves to the central side by 24 hr. The maximal increases at 40 hr in DRG and at 32 hr in SCG 
occur 16 to 24 hr after those seen in the end organs. These results suggest retrograde axonal transport to the ganglia of the NGF 
induced in the peripheral tissues in a manner similar to that occurs physiologically. 
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Figure 2. Total number of regenerated myelinated axons in 
the proximal portion (part I) and at the midpoint (part III) 
of the lesioned sciatic nerve of control group (A), 4MC-
treated group (B), antibody-applied group (C) and 4MC-
treated and antibody-applied group (D) at 5 weeks after 
the transection. The values are the mean ± SD (n = 6). 
^Significance, p < 0.001 (Student's t test). 
nerve of each group is shown in Figure 2. 
SUPPRESSION OF PERIPHERAL NEUROPATHIES 
Decrease in NGF content in the sciatic nerve (43) and rate of the 
sciatic nerve regeneration (44)isfoundinstreptozotocin(STZ)-
induced diabetic rats. These findings suggest a close relationship 
between NGF action and sciatic nerve regeneration. Recent work 
reveals a fall in sciatic motor nerve conduction velocity (MNC 
V) and a significant reduction of NGF content in the sciatic nerve of 
STZ-induced diabetic rats (45). 4MC treatment of these rats for 4 
weeks, starting from the STZ injection, results in an elevation of 
NGF content and prevents the reduction of MNCV, but exerts no 
effect on high glucose levels (45). These results suggest that 
decreased NGF levels in the sciatic nerve of experimental 
diabetic rats may be involved in the development of neuropathic 
process, also reported in human diabetic neuropathy (45a). 
4MC treatment may compensate for the inhibitory effect of 
STZ on the NGF level in diabetic neuropathy. Further experiments 
show that the 4MC treatment, started four weeks after STZ 
injection, result in higher NGF content, faster MNCV, and larger 
mean diameter of myelinated nerve fibers, compared with 
untreated rats (46). Taken together these findings demonstrate 
that 4MC treatment, via stimulation of NGF 
synthesis, may represent a viable neuroprotective strategy for 
the therapy of diabetic neuropathy (46a for neurotrophins, 
particularly, NGF in the therapy of human diabetic neuropathy). 
The potential efficacy of 4MC on an experimental model of the 
die-back type of peripheral neuropathy is also examined, using 
acrylamide monomer (ACR)-induced neuropathy in rats. This 
neuropathy results in a significant reduction in both MNCV and 
density of large myelinated fibers. In rats, 4MC, administered 
intraperitoneally together with ACR, improve clinical signs, and 
significant increase in NGF content in the sciatic nerves, faster 
MNCV, and greater myelinated fiber density than in rats given 
ACR alone (47). These findings suggest that 4MC can prevent 
the progression of ACR-induced neuropathy, in which decreased 
NGF levels may be involved. 
ENHANCEMENT OF BDNF SYNTHESIS 
As described above, the range of 4MC actions extends to 
effects on NGF-nonresponsive motor and sensory neurons 
(42,47), suggesting that 4MC could stimulate synthesis ofncu-
rotrophic factors other than NGF. Indeed, in cultured rat hip-
pocampal neurons, the secretion of BDNF is increased when 
4MC is added, while 4MC does not induce such an effect on 
NGF, NT-3, or glial cell line-derived neurotrophic factor (48). 
This suggests a selective action of 4MC on BDNF gene 
expression in hippocampal neurons, both in vitro and in vivo. 
In next experiments, infant rats less than 10 day s old, at which 
time the BBB is not yet fully established (49), are used, so that 
4MC might better penetrate into the brain. Dose-dependent 
enhancement of mRNABDNF expression, estimated by in situ 
hybridization, is observed in neurons of the whole brain, including 
the cerebral cortex, hippocampus, thalamus, and cerebellar 
Purkinje cells (48,50) (Fig. 3). However, the expression of 
mRNANGF in the infant rat brain is not detected, irrespective of the 
period and dosage of 4MC administration. Time-related 
changes in mRNABDNFand BDNF-like immunoreactivity are 
chased in the cerebral cortex following a single intraperitoneal 
injection of 4MC (50) (Fig. 4). mRNABDNFis maximally elevated at 1 
h, decreased from 3 h, and recovered to the pretreatment level by 12 
hpost-4MC injection in layers II/III and V of the cerebral cortex. 
BDNF-like immunoreactivity is elevated markedly in layer V 
and slightly in layer II/III 3 h after the injecti on, and the increased 
levels were sustained even at 12 h in layers II/III and V. Western 
immunoblot analysis shows that BDNF-like increases time-
dependently from 6 to 15 h before recovering to the pretreatment 
level by 24 h after the 4MC injection. These findings demonstrate 
that 4MC, penetrating into the BBB, strongly stimulates brain 
BDNF synthesis in the rat. 
INFLUENCES ON CALBINDIH D-28 EXPRESSION 
Brain BDNF synthesis induced by 4MC may affect certain 
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Figure 3. Enhanced expression ofmRNA
SDNF
 in an infant rat brain following repetitive administration of4MC. Newborn rats were 
injected intraperitoneally with vehicle alone, or with 10 or 150 \ig of4MC/kg body weight at 12-hr intervals for 10 days. The rats 
were anesthetized and cardioperfused with cold4%paraformaldehyde 4 hr after the final injection of 4MC before brain sections of 
each group were hybridized with antisense or sense cRNA probe for mRNA
BDNF
. Digoxigenin-labeled cRNA probes were 
generatedwithT? or SP6RNApolymerase using pGEM-7Zf(+)plasmidwithafull-length mouse BDNFcDNAas a template. 
  
pression of calbindin D-28, because it expresses during neuronal 
maturation (51), and is induced by BDNF in cultured neurons 
(52). 4MC that was intraperitoneally administered for 10 days to 
newborn rats elicited significant increases in calbindin D-28 
immunoreactivity in dentate granule cells, mossy fibers, and 
CA3 stratum lucidum of the hippocampus, and certain neuronal 
populations in the pyriform cortex (50). These findings suggest 
that subchronic 4MC administration accelerates physiological 
neuronal differentiation, probably through enhanced BDNF 
production. 
POTENTIAL OF 4MC AS A THERAPEUTIC AGENT 
4MC is believed to be incorporated into the cells via a mechanism 
similar to that for uptake 2 of catecholamines (33). Also, 4MC 
regulates NGF gene expression via both protein kinase C- and 
cAMP-independent mechanisms in cultured astrocytes (53). A 
long-lasting enhancement of c-jun mRNA expression is also 
caused by 4MC (54), which generates AP-1 proteins that drive 
NGF gene expression (55). However, AP-1 is not required for the 
activation of BDNF gene (56). The stimulatory effect on 
mRNA
BDNF
 expression is, so far, reported for agents which increase 
cAMP levels in astrocytes (57), forlipopolysaccharide in 
microglia (58), and for glutamate receptor agonists in neurons 
(12,13,56,59). Although these observations suggest an 
involvement of c-AMP dependent- and/or Ca
2+
-induced signal- 
ing, at present, there are no plausible mechanisms that explain 
4MC actions on BDNF gene expression. The most serious 
problem of 4MC for therapeutic use is a difficulty to cross the 
BBB of matured brains. It is reported that the BBB is partially 
destroyed in some neurological disorders, such as multiple 
sclerosis and Alzheimer's disease (60-62). In fact, repetitive 
peripheral administration of 4MC enhances mRNA
BDNF 
expression in infant rats, in which BBB is not yet fully established. 
Otherwise, chemical modifications that can deli ver4MC into the 
brain would be promisingforpatients with heal thy BBB functions. 
By peripheral administration, Kourounakis et al (63) have 
succeeded to deliver a substantial level of 4MC esterized with 
dihydropyridine into the brain, and observed significant elevation 
of brain NGF content. 
Recent investigations have added novel roles of BDNF for 
CNS, such as facilitation of neural transmission (64-66), synapse 
formation (67,68), synapse plasticity (69,70), regulation of 
growth of dendrites and axons (71-73), and also expression of 
genes acting on brain development (74-76). Furthermore, 
stimulating environment exerts positive effects on cerebral 
health via increased BDNF expression (77). These observations 
demonstrate the importance of BDNF for brain to develop, 
maintain functions, and protect neurons from various insults, 
and suggest that drug-induced enhancement of brain BDNF 
synthesis is profitable for prevention and amelioration of 
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Figure 4. Transient increases in the expression of mRNA
BDNF
 and BDNF-like immunoreactivity in the 
cereb
ral cortex after a single injection of 4MC. A single injection of 4MC in 10 jj.1 was administered intraperitoneally to 7-day-old 
rats at 150 p.g/kg body weight. The rats were anesthetized and cardioperfused with cold 4% paraformaldehyde at 0, 1, 3 and 
12 hr after the 4MC injection. Frozen brain sections of 10 jMn thickness were used for in situ hybridization (upper side) and 
immunostaining (lower side) experiments. 
  
findings that 4MC can elevate in vivo brain BDNF content and/ 
or mRNABDNF expression should be noticed. 
INVOLVEMENT OF NEUROTROPHIN SYNTHESIS IN 
PATHOBIOLOGY AND THERAPY OF NEUROLOGICAL 
DISEASES 
Recent studies suggest that estrogen replacement therapy can 
reduce the risk and severity of AD-related dementia in post-
menopausal women (78-80). Estrogen is shown to protect 
against ischemic injury (81) and neurotoxic effects of p-amylo-id 
(81,82), increase synaptic sprouting (83), and enhance the 
functional status of cholinergic projections to the hippocampus 
and cortex (84), resembling to the action of NGF and/or BDNF. 
Indeed, estrogen is proved to stimulate both mRNANOF and 
mRNABDNFexpression in rats in vitro and in vivo (85). It is likely 
that at least a part of estrogen action is mediated by an 
enhancement of NGF and/or BDNF production. Further, the 
cAMP system is involved in antidepressant action (86,87). 
Chronic administration of antidepressants, including selective 
serotonin reuptake inhibitor, stimulates the cAMP pathway 
such as expression of cAMP response element binding protein 
(CREB)(86). AsBDNFgenecanbealsoregulatedbyCREB(88), 
BDNF is likely to be involved in antidepressant actions and the 
pathophysiology of depression. Indeed, stress decreases 
mRNABDNF expression (89,90), which may contribute to the 
atrophy and dysfunction of hippocampal neurons (91,92). In 
50 
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contrast, antidepressant treatment increases the expression of 
hippocampal BDNF (93), and thereby reverses the stress-
induced neuronal atrophy or protects neurons from further 
damage. Altogether, upregulation of c AMP and BDNF may be a 
new target for the development of antidepressant agents (93; 94, 
this volume of Biomedical Reviews). And, agents other than 
4MC that also enhance the synthesis of NGF exert neuro-
protective effects in both ischemic brain injury (95-103) and 
diabetic neuropathy (104,105). 
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